Halil Tuna AKAR, Yılmaz YILDIZ, Kısmet ÇIKI, Ayşe Burcu KAHRAMAN, İzzet ERDAL, Turgay COŞKUN, Hatice Serap SİVRİ, Ayşegül TOKATLI, Gökhan GÜVENKAYA, Ali DURSUN

Single Institutional Experience with GM1 Gangliosidosis: Clinical and Laboratory Results of 14 Patients

Background: GM1 gangliosidosis is an autosomal recessive lysosomal storage disease caused by biallelic mutations in the GLB1 gene. Neurodegeneration, hypotonia, visceromegaly, macular cherryred spots, skeletal dysplasia, and coarse and dysmorphic face are the major clinical features. Aims: To evaluate the demographic and clinical data of patients with GM1 gangliosidosis in a single center. Study Design: A retrospective clinical study. Methods: This study included patients followed at Hacettepe University İhsan Doğramacı Children’s Hospital Pediatric Metabolism Unit with the diagnosis of GM1 gangliosidosis between 1988 and 2021. Hospital records of the patients were reviewed for demographic, clinical, and laboratory findings. Results: Fourteen patients were included in the study and 10 (71.4%) were male. The age at onset of clinical symptoms was between 0 and 5 months, and the median time to diagnosis after the first symptom was 4.3 (0-13) months. Motor delay (54%) was the most common initial symptom. The median follow-up period was 14.8 (0.4-92.2) months. Twelve patients (85.7%) died, and all deaths occurred before the age of 24 months. The median survival was 21.3 (95% confidence interval, 15.5-24.9) months. Higher leukocyte beta-galactosidase activity correlated with later age at onset (ρ = 0.575), later age at diagnosis (ρ = 0.618), and longer diagnostic delay (ρ = 0.702) (ρ < 0.05). Conclusion: Median survival in patients with GM1 gangliosidosis is less than 24 months. Beta-galactosidase enzyme activity may be associated with clinical onset and time of diagnosis in these patients.

PDF

___

Brunetti-Pierri N, Scaglia F. GM1 gangliosidosis: review of clinical, molecular, and therapeutic aspects. Mol Genet Metab. 2008;94:391-396. [CrossRef]
Arash-Kaps L, Komlosi K, Seegräber M, et al. The clinical and molecular spectrum of GM1 gangliosidosis. J Pediatr. 2019;215:152-157.e3. [CrossRef]
Tonin R, Caciotti A, Procopio E, et al. Pre-diagnosing and managing patients with GM1 gangliosidosis and related disorders by the evaluation of GM1 ganglioside content. Sci Rep. 2019;9:17684. [CrossRef]
Lawrence R, Van Vleet JL, Mangini L, et al. Characterization of glycan substrates accumulating in GM1 Gangliosidosis. Mol Genet Metab Rep. 2019;21:100524. [CrossRef]
Sperb F, Vairo F, Burin M, Mayer FQ, Matte U, Giugliani R. Genotypic and phenotypic characterization of Brazilian patients with GM1 gangliosidosis. Gene. 2013;512:113-116. [CrossRef]
Morrone A, Bardelli T,Donati MA, et al. beta-galactosidase gene mutations affecting the lysosomal enzyme and the elastin-binding protein in GM1-gangliosidosis patients with cardiac involvement. Hum Mutat. 2000;15:354-366. [CrossRef]
Lang FM, Korner P, Harnett M, Karunakara A, Tifft CJ. The natural history of Type 1 infantile GM1 gangliosidosis: A literature-based meta-analysis. Mol Genet Metab. 2020;129:228-235. [CrossRef]
Tasso MJ, Martinez-Gutierrez A, Carrascosa C, Vazquez S, Tebar R. GM1- gangliosidosis presenting as nonimmune hydrops fetalis: a case report. J Perinat Med. 1996;24:445-449. [CrossRef]
Denis R, Wayenberg JL, Vermeulen M, et al. Hyperphosphatasemia in early diagnosed infantile GM1 gangliosidosis presenting as transient hydrops fetalis. Acta Clin Belg. 1996;51:320-327. [CrossRef]
Sinelli MT, Motta M, Cattarelli D, Cardone ML, Chirico G. Fetal hydrops in GM(1) gangliosidosis: a case report. Acta Paediatr. 2005;94:1847-1849. [CrossRef]
Lee JS, Choi JM, Lee M, et al. Diagnostic challenge for the rare lysosomal storage disease: Late infantile GM1 gangliosidosis. Brain Dev. 2018;40:383-390. [CrossRef]
Bilim N. 2018 Türkiye Nüfus ve Sağlık Araştırması Temel Bulgular . 2019. http:// www.openaccess.hacettepe.edu.tr:8080/xmlui/bitstream/handle/11655/23356/2018_ TNSA_Ozet_Rapor.pdf?sequence=1&isAllowed=y[CrossRef]
Hiz Kurul S, Oktay Y, Töpf A, et al. High diagnostic rate of trio exome sequencing in consanguineous families with neurogenetic diseases. Brain. 2022;145:1507-1518. [CrossRef]
Ozkara HA, Topçu M. Sphingolipidoses in Turkey. Brain Dev. 2004;26:363-366. [CrossRef]
Kara DÖ, Şahpaz A. Pathological findings of central nervous system, two GM1 gangliosidosis autopsy cases. Turk J Pediatr. 2019;61:953-957. [CrossRef]
Yüksel D, Öksüz Ş, Senbil N. Extensive mongolian spots associated with GM1 gangliosidosis. Çocuk Sağlığı ve Haslıkları Dergisi. 2007;50:189-192. [CrossRef]
Regier, D.S., C.J. Tifft, and C.E. Rothermel, GLB1-Related Disorders, in GeneReviews(®), M.P. Adam, et al., Editors. 1993, University of Washington, Seattle
Jarnes Utz JR, Kim S, King K, et al. Infantile gangliosidoses: Mapping a timeline of clinical changes. Mol Genet Metab. 2017;121:170-179. [CrossRef]
Utz, J.R.J., et al., Infantile gangliosidoses: mapping a timeline of clinical changes. Molecular genetics and metabolism, 2017. 121(2): p. 170-179. [CrossRef]
Deodato F, Procopio E, Rampazzo A, et al. The treatment of juvenile/adult GM1- gangliosidosis with Miglustat may reverse disease progression. Metab Brain Dis. 2017;32: 1529-1536. [CrossRef]
Fischetto R, Palladino V, Mancardi MM, et al. Substrate reduction therapy with Miglustat in pediatric patients with GM1 type 2 gangliosidosis delays neurological involvement: A multicenter experience. Mol Genet Genomic Med. 2020;8:e1371. [CrossRef]
Garzone A, Pompilio A, Ciuccarelli F, et al. CPC-086 miglustat off-label in a paediatric formulation for a rare metabolic disease: early infantile GM1 gangliosidosis. Eur J Hosp Pharm. 2013;20:A1-A238. [CrossRef]
Nicoli ER, Annunziata I, d’Azzo A, Platt FM, Tifft CJ, Stepien KM. GM1 Gangliosidosis-A Mini-Review. Front Genet. 2021;12:734878. [CrossRef]
Yakin K, Urman B, Balaban B. Dynamic view of assisted reproduction in Turkey from 1996 to 2020. Reprod BioMed Online. 2022;44:747-754. [CrossRef]
Olgac A, Gulenc N, Kasapkara CS, Kilic M, Senel S, Tumer L. The intersection of two global problems: Refugees and inborn errors of metabolism. Annals of Medical Research. 2021; 28:296-302. [CrossRef]
Seven M, Paşalak Şİ, Sahin E, Akyuz A. Genetic Literacy of pregnant women and their use of prenatal screening and diagnostic tests in Turkey. J Genet Couns. 2019;28:578-586. [CrossRef